CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, announced financial results for the second quarter ended June 30, 2023, and provided a corporate update on its programs.
GSK plc (LSE/NYSE: GSK) announced that AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is now available in the US at all major retail pharmacies.
Wheeler Bio, Inc., an agile, boutique, clinical contract development and manufacturing organization (CDMO) announced the appointment of Marc Helouin as Chief Quality and Regulatory Officer (CQRO).
Bridge to Life Ltd., a leading global supplier of organ preservation and perfusion technologies, announced results from interim analysis of its multicenter, randomized, controlled liver clinical trial presented at the 2023 American Transplant Congress (ATC).
Young Pharmaceuticals, Inc., a leading provider of physician-dispensed skincare, announces an exclusive distribution agreement with Boulder-based TrulyO2, a maker of proprietary topical micro-oxygen delivery products.
RedShift BioAnalytics (RedShiftBio®) announces the launch of Aurora, the company's latest system using ground-breaking MMS technology.
Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving nearly 38 million members nationally, announced that Mostafa Kamal will succeed Ken Paulus as President and CEO of Prime Therapeutics.
Fresenius Kabi announced the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product.
Fresenius Kabi announced that its Ivenix® Infusion System has been selected by the Metrodora Institute to meet the Institute’s infusion medicine needs. The Metrodora Institute is an integrated, multidisciplinary medical and research center dedicated to treating neuroimmune axis disorders.
Microba Life Sciences Limited announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease (IBD).